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Introduction: Genetic skeletal diseases (GSDs) are a diverse and complex
group of rare genetic conditions that affect the development and homeosta-
sis of the skeleton. Although individually rare, as a group of related diseases,
GSDs have an overall prevalence of at least 1 per 4,000 children. There are
currently very few specific therapeutic interventions to prevent, halt or
modify skeletal disease progression and therefore the generation of new
and effective treatments requires novel and innovative research that can
identify tractable therapeutic targets and biomarkers of these diseases.
Areas covered: Remarkable progress has been made in identifying the genetic
basis of the majority of GSDs and in developing relevant model systems that
have delivered new knowledge on disease mechanisms and are now starting
to identify novel therapeutic targets. This review will provide an overview
of disease mechanisms that are shared amongst groups of different GSDs
and describe potential therapeutic approaches that are under investigation.
Expert opinion: The extensive clinical variability and genetic heterogeneity of
GSDs renders this broad group of rare diseases a bench to bedside challenge.
However, the evolving hypothesis that clinically different diseases might share
common disease mechanisms is a powerful concept that will generate critical
mass for the identification and validation of novel therapeutic targets and
biomarkers.
Keywords: achondroplasia, cartilage, cell signalling, endoplasmic reticulum stress, genetic
skeletal disease, multiple epiphyseal dysplasia, pseudoachondroplasia, skeletal dysplasia
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1. Introduction
Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare
genetic conditions that primarily affect the development and homeostasis of the
osseous skeleton [1,2]. Although individually rare, as a group of related genetic
diseases, GSDs have an overall prevalence of at least 1 per 4,000 children, which
extrapolates to a minimum of 225,000 people in the European Union. This burden
in pain and disability leads to poor quality of life and high healthcare costs.
There are more than 450 unique and well-characterized phenotypes that range in
severity from relatively mild to severe and lethal forms and are described in detail in
the 2011 Nosology and Classifications of the GSDs [1]. Forty different diagnostic
groups have been recognized to date, which are defined by a combination of molec-
ular, biochemical and/or radiographic criteria. The 2011 Nosology includes
316 conditions associated with one or more of 226 different genes; however, the
continued genetic and molecular characterization of GDSs has led to a better
defined clinical-molecular classification and a greater understanding of their
aetiology [2]. The generation and in-depth analysis of relevant cell and animal
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models has also increased our understanding of disease mech-
anisms and has identified phenotype-specific disease signa-
tures through ‘omics’-based analysis.
GSDs are difficult human diseases to treat, particularly
when the pathological process begins before birth and can
affect the entire skeletal system. Furthermore, since it is now
known that the skeleton has close physiological relationships
with many other tissue systems in the body, and mutant genes
may have pleiotropic effects, patients affected by GSDs may
also have serious complications with other organs, including
the peripheral nervous system, brain, bone marrow, immune
system, pancreas, kidney, heart, muscle and tendon.
The translation of state-of-the-art technology into quantifi-
able patient benefits such as the development of new treat-
ments or effective biomarkers has been extremely limited for
GSDs. The few notable exceptions include Biomarin’s drug
candidate for achondroplasia (ACH), a C-type natriuretic
peptide (CNP) analogue PG-CNP37 (BMN-111) [3],
bisphosphonate treatment for OI [4] and fibrous dysplasia [5],
enzyme replacement in lysosomal storage diseases [6] or
hematopoietic stem cell transplantation for infantile osteopet-
rosis [7]. This review will explore a select range of GSDs and
propose shared disease mechanisms that hold the promise as
potential therapeutic targets.
2. Genetic mouse models provide new insight
into shared disease mechanisms
Over the last 20 years, the generation and in-depth analysis of
transgenic, knock-out, knock-in and ENU-derived mice
models of GSDs have generated valuable knowledge of disease
mechanisms in vivo. Several recent reviews have highlighted
both strengths and weaknesses of various modelling
approaches [8]; however, these methodologies are still the
gold standard for generating relevant in vivo models to inves-
tigate skeletal pathobiology. These will also act as pre-clinical
models when new therapeutic targets are identified and
validated.
3. ER stress is a shared mechanism and
therapeutic target in a range of GSDs
resulting from dominant-negative mutations
in cartilage structural proteins
The extracellular matrix (ECM) of cartilage is a highly orga-
nized composite material comprising numerous structural
macromolecules such as collagens (Types II, IX, X and XI),
proteoglycans (aggrecan) and glycoproteins (matrilin-3 and
cartilage oligomeric matrix protein [COMP]). Mutations
have now been identified in all the genes encoding the major
structural components of the cartilage ECM and result in a
diverse group of both dominant and recessive GSDs. These
assorted mutations fall into two broad classes: qualitative
mutations, such as those that have dominant-negative (anti-
morphic) effects, and quantitative mutations that result in
haploinsufficiency and/or a complete loss of protein function.
This section will focus specifically on dominant-negative
(antimorphic) mutations, which affect conserved residues
that are structurally and functionally important for normal
protein folding and function (Table 1).
The endoplasmic reticulum (ER) is a distinct organelle of
eukaryotic cells and plays the major role in the synthesis, fold-
ing and trafficking of proteins entering the secretory pathway.
The ER has a highly sophisticated quality control mechanism
for ensuring that misfolded mutant proteins do not accumu-
late in, or enter the secretory pathway. Eukaryotic cells have
a homeostatic mechanism for maintaining the protein-folding
equilibrium of the ER, which is known as the unfolded pro-
tein response (UPR) [9]. However, the UPR has evolved to
resolve short-term acute ER stress such as high protein load,
heat shock or ischemia, but not prolonged ER stresses due
to rare events such as the misfolding of mutant proteins in
human genetic diseases [10]. A prolonged UPR can eventually
have detrimental effects on chondrocyte phenotype, differen-
tiation and viability [10].
An extensive allelic series of glycine and non-glycine substi-
tutions in type II collagen have been introduced into mice to
model a diverse range of type II collagenopathies [11,12].
A common feature in many of these mouse models was the
evidence of ER stress, translating in some cases into a reduc-
tion in chondrocyte proliferation and an increase in apoptosis.
Moreover, the recent development of induced pluripotent
stem (iPS) cells, and their differentiation into relevant cell
types such as chondrocytes (iChon), has allowed the in-depth
analysis of cells from patients with various type II
Article highlights.
. Endoplasmic reticulum stress is a shared disease
mechanism and potential therapeutic target in a diverse
range of Genetic skeletal diseases (GSDs) resulting from
dominant-negative mutations in cartilage structural
proteins.
. Disruption to protein trafficking in chondrocytes leads to
a variety of chondrodysplasia phenotypes, which
highlights that ‘professionally secreting cells’ such as
chondrocytes are highly susceptible to perturbations in
ER homeostasis and defects in protein trafficking and
secretion.
. The incorporation of mutant proteins into the
extracellular matrix leads to changes in the composition
and properties of cartilage.
. Reduced chondrocyte proliferation, increased and/or
dysregulated apoptosis are common downstream effects
for a range of different GDS and are robust readouts for
pre-clinical studies.
. Numerous GSDs result from mutations affecting
signalling pathways in cartilage and these are the
targets of new therapeutic interventions.
This box summarizes key points contained in the article.
M. D. Briggs et al.
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collagenopathies and the testing of potential corrector mole-
cules such as trimethylamine N-oxide (TMAO) [13], which is
a chemical chaperone that can alleviate mutant protein aggre-
gation and ER stress [14,15]. These studies have provided pre-
liminary proof-of-principle evidence that molecular
chaperones may serve as therapeutic drug candidates [13].
The role of ER stress in GSDs might best be exemplified by
mutations in COMP, matrilin-3 and type X collagen resulting
in pseudoachondroplasia (PSACH), multiple epiphyseal dys-
plasia (MED) [8] and metaphyseal chondrodysplasia type
Schmid (MCDS), respectively (Figure 1 & Table 1) [16].
Over the last 10 years, the extensive analysis of mouse models
for the MATN3 (V194D) [17], COMP (D469del, T585M)
[18,19] and COL10A1 (N617K) [16] mutations has been per-
formed, which has allowed a direct comparison of disease
mechanisms [8,20]. Furthermore, the application of ‘omics’-
based investigations (mRNA and protein) has allowed
genotype-specific disease signatures to be derived and either
shared or discrete downstream genetic pathways to be
identified [8,18,21,22].
Interestingly, bothMatn3 (V194D) and Col10a1 (N617K)
mutations cause misfolding and retention of the relevant
mutant protein, inducing ER stress and a classical UPR, pri-
marily characterized by the up-regulation of ER chaperones
BiP, Grp94 and a range of protein disulphide isomerases
(PDIA) [21,22]. Hartley and colleagues [23] commented on a
similar increase in specific PDIAs (PDIA1, 3, 4 and 6) in
chondrocytes from Col10a1N617K and Matn3V194D mutant
mice and also noted that two novel ER stress-related genes,
Armet and Creld2, were also significantly upregulated in these
Constitutively activating mutations
ACH/TD/HCH/SADDAN (FGFR3)
Jansen's metaphyseal chondrodysplasia (PTHlR)
Brachyolmia type 3 & metatrophic dysplasia (TRPV4)
Fibrous dysplasia (GNAS)
Disrupted ECM organisation
PSACH (COMP)
MED types 2, 3 & 6 (type IX collagen)
MCDS (type X collagen)
Fibrochondrogenesis 1 (type XI collagen)
SEMD, aggrecan type
OCD, aggrecan type
Type II collagenopathies
Schneckenbecken dysplasia (SLC35D1)
Diastrophic dysplaisa (SLC26A6)
Haploinsufficiency for ECM components
Stickler syndrome type I (type II collagen)
Stickler syndrome type 4, 6 & 6 (type IX collagen)
MCDS (type X collagen)
Fibrochondrogenesis 1 (type XI collagen)
SED-Kimberley (aggrecan)
Idiopathic short stature (aggrecan)
Disrupted trafficking of cargo
SMED-JL (DDR2)
SED-tarda(TRAPPC2)
Achondrogenesis type I (TRIP11)
Cranio-lenticulo-sutural dysplasia (SEC23A)
bulldog/crusher/feelgood zebrafish
Mutant protein retention and ER stress
PSACH (COMP)
MED types 1 & 5 (COMP & matrilin-3)
MCDS (type X collagen)
Fibrochondrogenesis 1 (type XI collagen)?
Type II collagenopathies
Figure 1. Schematic showing chondrocytes and pericellular cartilage matrix from the growth plate of a 1-week-old wild type
mouse. Five fundamental disease mechanisms are highlighted along with a selection of associated genetic skeletal diseases.
Disease Key: ACH: Achondroplasia; TD: Thanatophoric dysplasia; HCH: Hypochondroplasia; SADDAN: Severe achondroplasia with developmental delay and
acanthosis nigricans; PSACH: Pseudoachondroplasia; MED: Multiple epiphyseal dysplasia; SMED-JL: Spondylo-meta-epiphyseal dysplasia short limb-hand type;
SED: Spondyloepiphyseal dysplasia; MCDS: Metaphyseal chondrodysplasia, Schmid type; SEMD: Spondyloepimetaphyseal dysplasia; OCD: Osteochondritis dissecans.
Gene Key: FGFR3: Fibroblast growth factor receptor 3; PTH1R: Parathyroid hormone 1 receptor; TRPV4: Transient receptor potential cation channel subfamily V
member 4; GNAS: Guanine nucleotide binding protein, alpha stimulating; COMP: Cartilage oligomeric matrix protein; DDR2: Discordin domain receptor 2;
TRAPPC2: Trafficking Protein Particle Complex 2; TRIP11: Thyroid Hormone Receptor Interactor 11; SEC23A: Sec23 homolog A.
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two models [23]. The cartilage-specific knock-out of both
Armet and Creld2 has resulted in mice with growth plate dys-
plasia, thus confirming their important role in skeletal devel-
opment (our unpublished observations). Moreover, the
recent cartilage-specific knock-out of PDIA3 (also called
ERP57/GRP58) caused ER stress resulting in reduced prolif-
eration and accelerated apoptotic cell death of chondrocytes
in the growth plate [24]. Finally, the cartilage-specific ablation
of an entire UPR branch (i.e. Xbp-1 signalling) also resulted
in a chondrodysplasia that was characterized by reduced
chondrocyte proliferation and leading to delayed cartilage
maturation and mineralization [25].
In contrast, the accumulation of mutant COMP has been
demonstrated to result in the induction of novel stress
pathways, which are characterized by changes in the expres-
sion of groups of genes implicated in oxidative stress (ER
dependent), cell cycle regulation and apoptosis [18,26,27]. In
this context, Posey and colleagues have recently demonstrated
that the postnatal administration of aspirin to a transgenic
dox-induced COMP-overexpression model of PSACH
abolished mutant COMP intracellular retention and had
beneficial effects on chondrocyte proliferation, apoptosis and
final bone length [28]. However, this study failed to show
increased secretion of wild type or mutant COMP upon
treatment and also to identify a mechanism by which aspirin
may reduce mutant COMP retention and modulate chondro-
cyte phenotype and bone growth in PSACH [28]. Neverthe-
less, these are interesting findings that require further
validation.
In summary, these recent studies using a complimentary
group of genetically relevant mouse models and cartilage-
specific knock outs have demonstrated the key role that ER
stress plays in the initiation and progression of growth plate
dysplasia and reduced bone growth (Figure 1). Moreover, pre-
liminary studies suggest that ER stress is a good therapeutic
target that can be influenced through small molecule interven-
tion, and to date, the use of trimethylamine N-oxide
(TMAO) [13], lithium, valproate [29], sodium phenylbutyrate
(SPB) [22,29] and various antioxidant and anti-inflammatory
agents [28] have been tested in both cell and mouse models
with varying degrees of success.
4. Disruption to protein trafficking in
chondrocytes leads to various
chondrodysplasia phenotypes through
different mechanisms
Missense mutations in the discordin domain receptor 2
(DDR2) have been shown to cause the rare autosomal reces-
sive spondyo-meta-epiphyseal dysplasia with short limbs and
abnormal calcifications (SMED-SL) due to either protein
trafficking defects or loss of ligand binding [30]. DDR2 is a
plasma membrane receptor tyrosine kinase that functions as
a collagen receptor and missense mutations in DDR2 result
in either its retention within the ER, or loss of collagen-
binding activity and transmembrane signalling. Both
mechanisms most likely lead to retention in the ER of the
DDR2 cargo (e.g. fibrillar collagens), thereby further exacer-
bating ER stress due to mutant DDR2 alone [30]. The deletion
of DDR2 in mice has previously been reported to cause
reduced chondrocyte proliferation and dwarfism [31], suggest-
ing a role for DDR2 in cell-matrix attachment and in patho-
logical conditions where increased cell proliferation and ECM
turnover are coupled (Table 2) [32].
Similarly, the ER export of procollagen is also controlled in
part by the ubiquitously expressed Sedlin (TrappC2), and
antimorphic or loss of function mutations in TRAPPC2 cause
X-linked spondyloepiphyseal dysplasia Tarda (SEDT) [33].
SEDT results from a chondrocyte-specific defect in the
trafficking and secretion of cartilage structural proteins,
specifically type II procollagen (Table 2) [34,35]. Moreover,
mutations in essential components of COPII-coated vesicles,
such as SEC23A, sec23a and sec24d, which transport secretory
proteins from the ER to Golgi, result in cranio-lenticulo-
sutural dysplasia (CLSD) [36] and the Zebrafish mutants
crusher [37] and bulldog [38], respectively. In all three condi-
tions, there is accumulation of proteins, in particular fibrillar
collagens, within the ER of relevant cell types (Table 2).
Finally, loss-of-function mutations in Golgin GMAP-210
(TRIP11) causes a lethal skeletal dysplasia in both mice and
humans (achondrogenesis type 1A) [39], which is characterized
by disrupted Golgi architecture and ER stress due to the intra-
cellular accumulation of perlecan (but not aggrecan or type II
collagen) eventually leading to abnormal chondrocyte differ-
entiation and increased apoptosis (Table 2) [39].
In summary, these various genetic studies consistently
demonstrate that ‘professionally secreting cells’ such as
chondrocytes are highly susceptible to perturbations in ER
homeostasis and defects in protein trafficking and secretion.
This premise is supported by the observation that deletion
or mutation of ubiquitously expressed components of the
secretory pathway specifically causes chondrocyte disruption
and cartilage defects (Figure 1). Modulation of the secretory
pathway in zebrafish mutants by brefeldin A treatment has
recently been demonstrated in polycystic kidney disease by
Le Corre and colleagues [40], who have proposed that
restoration of normal rates of secretory protein synthesis and
secretion may be a new target in the treatment of autosomal
dominant trafficking defects.
5. Incorporation of mutant proteins into the
ECM leads to cartilage defects and GSDs
The retention of mutant protein in the ER of cells appears to
be a major pathomolecular mechanism underpinning the dis-
ease aetiology in a range of GSDs (Figure 1). Therefore, one of
the potential targeting avenues suggested in the literature is
the use of molecular chaperones, which are small molecules
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that could potentially aid in the degradation and/or secretion
of the mutant proteins into the cartilage ECM [41].
The potential effectiveness of such treatment has been dem-
onstrated for type IV collagen mutations causing hemorrhagic
stroke. In a study described by Murray and colleagues [42], two
related individuals carrying the same missense mutation pre-
sented with differing severity of cerebral haemorrhaging;
whilst the parent appeared unaffected, his son showed
symptoms of severe porencephaly. In fibroblast cell lines
from both individuals, the mutant protein was secreted and
incorporated into the ECM of the basement membrane
causing morphological abnormalities. However, the cells
from the severely affected son secreted less collagen IV and
showed an increased retention of the mutant protein in the
rER. Treatment with a molecular chaperone (sodium phenyl
butyrate) appeared to alleviate the ER stress and restore
protein secretion to some extent, thus presenting a promising
thera eutic avenue [42].
However, it is important to note that the incorporation of
mutant proteins into the ECM may also have deleterious
effects and lead to a skeletal condition, as highlighted by the
PSACH and MED-causing mutations in the C-terminal
domain (CTD) of COMP [19]. In several-documented cases
CTD mutant COMP protein is secreted, eliciting either a
mild ER stress or no ER stress at all, yet still resulting in dys-
plasia. The incorporation of mutant COMP into the ECM
results in abnormal fibrillar and proteoglycan composition,
leading to abnormal chondrocyte clustering, a decrease in
proliferation and eventually apoptosis [19]. Moreover, changes
in cartilage ECM composition has also been detected in some
type II collagenopathies (SEDc and Kniest Dysplasia), dia-
strophic dysplasia (DTDST) where the cartilage shows signs
of under-sulphation of proteoglycans and other ECM abnor-
malities [43], and finally Schneckenbecken dysplasia where the
ECM abnormalities result from a loss-of-function mutation
to the SLC35D1 nucleotide-sugar transporter [44]. In all these
examples, the ECM defects lead to an altered tissue morphol-
ogy and cellular organization, thereby affecting the chondro-
cyte columnar arrangement in the proliferative zone of the
growth plate and ultimately impacting on long bone growth.
An in-depth analysis of the structural proteins in the
cartilage ECM, in particular the proteins that have a bridg-
ing/adaptor function in the ECM, using transgenic mouse
models has shown that some of these molecules are actually
redundant in cartilage. For example, the genetic deletion of
COMP [45], matrilin-3 [46], matrilin-1 [47], type IX collagen [48]
and WARP [49] had no effect on gross cartilage structure and
long bone growth. Therefore, one can postulate that silencing
the defective alleles may pose an exciting therapeutic avenue
for skeletal dysplasias resulting from mutations in structural
proteins [50]; in fact, Posey and colleagues have tested this
approach by using RNA interference [51]. In this particular
study, the authors used short hairpin RNA to knock down
the expression of both wild-type and mutant COMP, thus
reducing the presence of mutant COMP inside and outsideT
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the cell [51]. However, this type of approach would not be
applicable for the most important structural molecules of
cartilage and bone, that is, the collagens and proteoglycans.
For example, haplo-insufficiency for type II collagen and
aggrecan leads to Stickler syndrome and SED-Kimberley,
respectively (Table 3), whereas a lack of perlecan is associated
with Schwartz-Jampel syndrome [1]. Interestingly, allele-
specific RNA silencing using siRNA has recently been
described as potential therapy for Meesmann epithelial cor-
neal dystrophy caused by a point mutation in the keratin
gene. Therefore, pending the development of effective meth-
ods to deliver such therapies to the dense and largely avascular
environment of cartilage, they nonetheless present an exciting
future therapeutic avenue.
Mutations that result from aberrant splicing often lead to
nonsense-mediated decay of mRNA and associated cell stress
or the production of truncated molecules, which may have
downstream dramatic effects. This is the case in some cases
of Schwartz-Jampel syndrome (SJS) and in dyssegmental
dysplasia, Silverman-Handmaker type (DDSH) where an
exon skipping mutation leads to a truncated perlecan
molecule [2]. However, it is sometimes possible to predict a
milder phenotype if the RNA splicing can be partially
restored, resulting in a shorter molecule but with a majority
of the domains in-frame and correctly folded. Such a rationale
was recently applied to the treatment of Duchenne muscular
dystrophy by attempting to restore partially functional dystro-
phin and thus reducing the severity of the disease to a milder
Becker muscular dystrophy-like phenotype. Whilst this
approach may not be suitable for all cases of GSD, it could
be applicable in those diseases where haploinsufficiency and/
or retention of the mutant protein leads to a severe pheno-
type, but a presence of the partially functional mutant mole-
cule in the ECM may lead to a milder condition, and is
therefore an interesting therapeutic avenue that could be
explored in the future.
6. Mechanosensing is important in the
pathobiology of GSDs
Primary cilium is an organelle existing on almost every cell
type in the human body [52]. In cartilage, cilia have been
Table 3. Disease mechanisms in selected GSDs resulting from haploinsufficiency for cartilage structural proteins.
Gene Protein Disease In Molecular mechanisms Cell and/or tissue mechanism
COL2A1 Type II
collagen
Stickler syndrome
type 1
AD Heterozygous nonsense mutations
or out of frame deletions leading to
frameshift
Presumed haploinsufficiency for type II
collagen
Potential antimorpic disruption to collagen
fibril structure and cartilage organization
COL9A1 Type IX
collagen
Stickler syndrome
type 4
AR Homozygous nonsense mutations Presumed haploinsufficiency for type IX
collagen
Potential antimorpic disruption to collagen
fibril structure and cartilage organization
Possible ER stress associated with the
degradation of excess collagen a(IX) chains
COL9A2 Stickler syndrome
type 5
Homozygous for predicted frame
shift mutations and a premature
termination codon
COL9A3 Stickler syndrome
type 6
Homozygous out of frame deletion
leading to frameshift and a
premature termination codon
COL10A1 Type IX
collagen
Metaphyseal chondro-
dysplasia, Schmid type
AD Heterozygous nonsense mutations
or out of frame deletions leading to
frameshift and a premature
termination codon
Haploinsufficiency for type X collagen due to
NMD of mRNA from mutant allele
Possible ER stress associated with NMD
Potential disruption to cartilage structural
organization
COL11A1 Type XI
collagen
Fibrochondrogenesis 1 AR Compound heterozygosity for a
loss-of-function mutation and an
antimorphic missense mutation
(glycine substitution)
Haploinsufficiency of a2(XI) collagen chains
due to NMD of mRNA from mutant allele
Possible ER stress resulting in a fibroblastic
appearance of the chondrocytes
Antimorpic disruption to collagen fibril
structure producing a fibrous ECM
COL11A2 OSMED/WZS AR Homozygous for nonsense
mutations
Absence of a2(XI) collagen chains
due to NMD of mRNA from mutant
alleles
Potential antimorpic disruption to collagen
fibril structure and cartilage organization
Possible ER stress associated with the
degradation of excess a1(XI) collagen chains
ACAN Aggrecan Idiopathic short stature AD Predicted frame shift mutations
leading to a premature termination
codon
Presumed haploinsufficiency for aggrecan
due to NMD of mRNA from mutant allele
Potential antimorpic disruption to cartilage
structure and tissue organization
SED Kimberley AD
AD: Autosomal dominant; AR: Autosomal recessive; ER: Endoplasmic reticulum; ECM: Extracellular matrix; GSDs: Genetic skeletal diseases; NMD: Nonsense-
mediated degradation.
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implicated in important signalling pathways (such as hedge-
hog and wnt signalling) and have been suggested as a mecha-
nosensory organelle on the cells [53]. Various ECM receptors,
including several integrins, are located on or within a close
vicinity of the primary cilia and may be important in regulat-
ing the cell--matrix interactions [54]. Furthermore, the primary
cilia length and prevalence are increased in osteoarthritic car-
tilage [55] and changes to the cilia organization have been
observed in skeletal dysplasias (our unpublished observations)
and chondrosarcoma tissues [56].
Disruptions to the columnar organization of proliferative
chondrocytes have been described in several mouse models
of rare skeletal conditions, in particular those where the
ECM structure was affected [57--61]. The change in cell align-
ment was not dissimilar from abnormalities seen in
cartilage-specific integrin knock-out mice, which indicated
that the disruption of the cell matrix interactions may in
fact be the underlying pathology [62,63]. Moreover, a truncat-
ing mutation in integrin a 10 leads to a canine chondrodys-
plasia [64]. From a therapeutic perspective, it is interesting to
speculate that the way a cell senses its environment could be
modulated. Indeed, such therapies have in fact been tried in
Crohn’s disease where the use of integrin antagonists has
shown a dramatic improvement in disease severity [65].
Mechanosensing is important for cartilage development
and homeostasis and mutations involving primary cilia
molecules have been discovered in several chondrodysplasias
to date, including the Verma-Naumoff syndrome, Majewski
syndrome, Jeune syndrome, Ellis-van Creveld syndrome, the
Sensenbrenner syndrome and Weyers acrofacial dysostosis [1].
In many cases of the skeletal ciliopathies, the underlying dis-
ease mechanism is the disruption to the hedgehog-signalling
pathway, which is an important pathway regulating cartilage
proliferation and differentiation. Interestingly, hedgehog sig-
nalling can be partially modulated and/or restored using small
molecular treatment, and several reagents including inducible
protein reagents based on the Gli1 and Gli3 transcription
factors as well as purmorphamine (a small-molecule agonist
of Smoothened) are able to activate the Hedgehog pathway
and are the proposed reagents currently tested for future
treatment of ciliopathies [66].
7. Changes to extracellular signalling can also
lead to skeletal dysplasia phenotypes
ECM molecules are important for the sequestration and
diffusion of endocrine, paracrine and autocrine molecules in
the dense cartilage tissue [67]. Mutations inducing changes in
the chemical and physical composition of the ECM may
therefore have detrimental effects on the signalling pathways
driving development and differentiation in cartilage. For
example, changes in Indian hedgehog signalling have been
detected in DTDST cartilage [68] and in transgenic mice
harbouring the deletion of exon 48 in the mouse alpha1(II)
procollagen gene [69].
Mutations in the genes encoding molecules important in
cartilage signalling have also been implicated in GSDs. Eiken
syndrome is a recessive skeletal condition resulting from a
truncating mutation in the parathyroid hormone-related pep-
tide type 1 receptor (PTHR1) and mutations in the PTHR1
have also been found in certain forms of Jansen dysplasia [2].
SHOX haploinsufficiency leads to perturbed programmed
cell death of hypertrophic chondrocytes and premature
epiphyseal fusion of the distal radius in patients. In the case
of truncating and loss of function mutations, silencing of
the defective receptors, the use of soluble agonists and activa-
tors of the signalling pathways or the use of soluble receptors
and enzyme replacement therapy (ERT) can all be proposed
as potential therapeutic avenues. For example, in the case of
hypophosphatasia due to loss of function mutations in the
gene encoding tissue-nonspecific alkaline phosphatase, asfo-
tase alfa (a first-in-class ERT) is undergoing evaluation [70--72].
Conversely, numerous GSDs result from activating
mutations affecting the signalling pathways in the cartilage [2].
Mutations within the fibroblast growth factor receptors
(FGFR) 1 -- 3 cause a wide range of skeletal disorders, includ-
ing diseases primarily characterized by craniosynostosis such
as osteoglophonic dysplasia (FGFR1, [73]), Apert (FGFR2, [74]),
Crouzon (FGFR2, [75]), Pfeiffer (FGFR1 and FGFR2, [76]),
Beare-Stevenson cutis grata (FGFR2, [77]) and Muenke
(FGFR3, [78]) syndromes, in addition to the dwarfing
syndromes ACH, hypochondroplasia and thanatophoric
dysplasia (all FGFR3, [79]). FGFRs are plasma membrane recep-
tor tyrosine kinases that mediate intracellular signalling upon
ligand binding. While the phenotypes of these disorders vary,
they all arise as a consequence of constitutive FGFR protein
activation, and disruption to downstream signalling cascades.
Other GSDs share this common disease basis with
activating mutations found in different genes causing diverse
disorders such as Jansen’s metaphyseal chondrodysplasia
(PTH1R) [80], fibrous dysplasia (GNAS, [81]) and brachyolmia
type 3 and metatrophic dysplasia (TRPV4) (Figure 1) [82].
Similar to FGFR1 -- 3, PTH1R encodes a cell surface receptor
(parathyroid hormone/parathyroid hormone-related peptide
receptor); however, downstream signalling occurs through
several different guanine-nucleotide binding proteins (G-pro-
teins) [83], while GNAS encodes the a subunit of one of these
G-proteins, Gsa. Constitutive activation of both PTH/
PTHrP and Gsa leads to the excessive synthesis of cyclic
AMP, disrupted chondrocyte signalling and bone pathol-
ogy [80,84]. Activating mutations in transient receptor potential
vallinoid family member 4 (TRPV4) leads to a delay in bone
mineralization and a spectrum of diseases from autosomal
dominant brachyolmia to lethal metatrophic dysplasia.
TRPV4 (transient receptor potential vanilloid 4) encodes a
calcium permeable cation channel and disease-causing muta-
tions constitutively activate this channel resulting in an
uncontrolled influx of calcium into chondrocytes, activation
of follistatin [85], increased inhibition of BMP activity [86]
and ultimately, improper bone formation (Figure 1). Finally,
M. D. Briggs et al.
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one of the best examples of this class of GSD is fibrodysplasia
ossificans progressive (FOP), which results from heterozygous
activating mutations in Activin receptor A, type I/Activin-like
kinase 2 (ACVR1/ALK2), a bone morphogenetic protein
receptor. The genetic basis of FOP and relevant therapeutic
targets and approaches has been extensively reviewed by Fred-
erick Kaplan and colleagues [87]. Briefly, targeting the bone
morphogenetic protein signalling pathway has been proposed
as a promising therapeutic target and palovarotene, a retinoic
acid receptor g agonist [88], is currently in Phase II clinical
trials for patients with FOP.
Existing therapies for GSDs caused by constitutively acti-
vating mutations remain limited, although insights into their
molecular pathogeneses have yielded some exciting therapeu-
tic targets (Table 4). A murine model introduced with a
dominant-negative FGFR1 construct in utero prevented suture
fusion within the skull [89], providing proof-of-principle that
the abnormal suture fusion of FGFR-related craniosynostosis
may be modulated by engineered FGFR receptors. Perhaps
more promising as potential therapies, both RNA interference
of FGFR2 and pharmacological inhibition of MEK-ERK
signalling have been shown to prevent abnormal skeletal
phenotypes in a mouse model of craniosynostosis and reduce
cranial suture fusion [90,91].
A significant development in efforts to treat ACH was the
discovery that CNP overexpression rescues the phenotype in
an ACH mouse model by inhibiting FGFR3 downstream sig-
nalling through the MAPK pathway [92]. Recent efforts have
focused upon optimizing the pharmacological properties of
CNP by designing and validating CNP analogues such as
BMN 111 [93,94], or improving production yields [95]. An
alternative to CNP-based therapy has involved the reposi-
tioned use of a FDA-approved drug (meclizine used for
treatment of motion sickness) [96]. In this study, human chon-
drosarcoma cells expressing constitutively active mutants of
FGFR3 that cause thanatophoric dysplasia, SADDAN and
achondrogenesis were treated in vitro with meclozine and
this ameliorated abnormally suppressed cell proliferation.
Comparison with the effect of CNP on the same cell models
revealed that meclozine was as efficient as CNP in attenuating
the abnormal FGFR3 signalling. Subsequent studies validated
this result in a mouse model of ACH, showing that the bone
lengths of both wild-type and mutant mice treated with
meclozine were significantly longer than in untreated
mice [97]. Given that meclozine is already an FDA-approved
drug, it is ideally positioned for assessment for clinical use
in the treatment of short stature in achondrogenesis.
The use of statins to treat FGFR3-related disorders, ACH
and tanatophoric dysplasia type I (TD1) has recently been
proposed [98]. Yamashita et al. have demonstrated that statins,
previously used in the treatment of tumours and of disorders
in the cardiovascular, nervous and immune systems, were able
to upregulate the expression of sox9, type II collagen and
aggrecan in cell and animal models of ACH and TD1 [98].
They have also demonstrated a decrease in the protein levels
of FGFR3 in the patient-derived induced pluripotent stem
cells (iPSCs) differentiated into the chondrogenic lineage
and in the Fgfr3Ach mouse model of ACH. Interestingly, the
decrease in the protein level did not correlate with a decrease
in mRNA level for FRFR3, which was actually slightly
increased upon the statin treatment. Treatment of chondro-
cytes derived from the Fgfr3Ach mice with lovastatin in the
presence of proteasomal inhibitors revealed that the statin
partially upregulated the proteosomal degradation of
FGFR3 in the treated cells and animals [98].
Several approaches have been proposed as possible thera-
peutic interventions for TRPV4-related disease [99]. Existing
agents capable of blocking the calcium-permeable TRPV4
channel (GSK2193874 [100] and HC-067047 [101]) represent
candidate drugs that would be highly appropriate for admin-
istration to mouse models of TRPV4-related disease [102] and
subsequent phenotypic analysis. Alternatively, inhibition of
TRPV4 protein expression using shRNA might be another
way to circumvent the harmful effect of uncontrolled calcium
influx into chondrocytes.
Perhaps the most effective clinically approved treatment for
a GSD caused by a constitutively activating mutation is the
intravenous administration of bisphosphonates to treat
fibrous dysplasia. This class of drugs possesses a common
basic structure similar to pyrophosphate that inhibits bone
resorption and has been used with success for decades. In
addition to a decreased turnover of bone, the radiological
aspect of existing bone lesions is improved, as is the experience
of pain reported by patients [103]; however, a subset of patients
remain nonresponsive to bisphosphonate treatment. The rela-
tively recent discovery of GNAS as the disease locus of fibrous
dysplasia raises the possibility of targeting the constitutively
active Gsa protein and downstream effectors in future
therapeutic interventions.
8. Reduced chondrocyte proliferation and
increased dysregulated apoptosis are the
downstream effects and a shared disease
mechanism of many GSD mutations
Several studies have recently demonstrated that reduced chon-
drocyte proliferation, increased and/or dysregulated apoptosis
in the growth plates of mouse models is a major pathological
component of various GSDs, including those resulting from
mutations in genes encoding cartilage structural proteins
(Comp, Matn3 and Col2a1) [8,12,104], a sulphate transporter
(Slc26a2) [105] and components of the trans-golgi network
(GMAP-210) [32]. These pathomolecular mechanisms are par-
ticularly relevant to those GSDs that have a significant epiph-
yseal involvement, such as PSACH-MED, DTDST and the
type II collagenopathies, but are perhaps not so relevant for
metaphyseal chondrodysplasias such at MCDS where the
pathology involves only non-proliferating hypertrophic
chondrocytes [16].
New therapeutic targets in rare genetic skeletal diseases
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Defining the relative contribution of reduced chondrocyte
proliferation, increased and/or dysregulated apoptosis to
growth plate dysplasia and reduced bone growth is experi-
mentally challenging; however, the study of novel ‘ER-stress
phenocopies’ has recently provided new insight into the spe-
cific impact of these different disease mechanisms [16,106,107].
The cartilage-specific expression of mutant forms of thyro-
globulin has confirmed that reduced chondrocyte prolifera-
tion resulting from an intracellular stress caused by the
accumulation of a misfolded protein and in the absence of
perturbations to apoptosis was sufficient to cause a significant
reduction in long bone growth [107].
In summary, these innovative studies therefore defined
reduced chondrocyte proliferation as a major determinant of
reduced bone growth in epiphyseal dysplasias, which holds
the promise of therapeutic intervention or as a robust readout
of drug efficacy in these pre-clinical models of GSDs.
9. Soft tissue complications are a common
factor in GSDs
Cartilage, bone, tendon, ligament and skeletal muscle are
all tissues of the mesenchymal lineage. It is therefore not
surprising that many of the structural molecules implicated
in GSDs are also expressed in more than one of these tissues.
Musculoskeletal complications are therefore an additional
complication that is important to consider in terms of clinical
management of GSDs. Patients with MED [108,109],
Camurati-Englemann disease [110,111], Marfan syn-
drome [112,113] and Schwartz-Jampel syndrome [114,115] present
with musculoskeletal complications (muscle weakness, muscle
stiffness, joint laxity, easy fatigue) that are often difficult to
diagnose upon biopsy alone. Understanding the disease mech-
anisms underlying these clinical complications is of utmost
importance, especially considering that these symptoms can
manifest prior to the onset of skeletal manifestations and
can lead to an initial misdiagnosis. Moreover, mesenchymal
tissues are highly mechanically responsive and able to regulate
gene expression depending upon the mechanical stimu-
lus [116,117]. It is therefore interesting to speculate that the
understanding of the musculoskeletal complications associ-
ated with GSDs may lead to a better physiotherapy regime
and management of the patients in the future.
10. Biomarkers are important for monitoring
disease progression and efficacy of
treatment
A lack of relevant disease biomarkers has been a key factor to
the delay in the development of new therapeutic targets,
largely due the interdependency between biomarker and
drug development pipelines [118]. Worryingly there are cur-
rently no reliable and readily quantifiable biomarkers that
allow pre-symptomatic diagnosis of most GSDs, or to
monitor responses to therapeutic regimes. This lack of
suitable specific biomarkers reflects the complexity of the bio-
marker pipeline, which involves the co-dependent processes of
identification, verification, validation and reliable detection
and quantification in easily obtained biological samples such
as blood, urine and cell culture medium.
The complete ECM portrait of bone and cartilage com-
prises a limited number of ~300 different components termed
the ‘core matrisome’ [118], which limits the available ‘pool’ of
potential proteins and/or degradation products that may be
found in serum. The determination of biomarkers in serum
or urine is widely used to screen for specific pathologies of
various organs. For example, individuals with skeletal disor-
ders can be monitored for biomarkers of bone formation,
bone resorption or cartilage degradation, which helps to dis-
criminate between different types of skeletal pathologies.
Moreover, the information obtained from this analysis can
be relevant for individual treatment regimes, for example,
not every patient displaying reduced bone mass will necessar-
ily profit from the commonly used anti-resorptive medica-
tion. In addition to the well-established relevance of
biomarkers in disease diagnosis and personalized treatment,
their altered concentrations can also be causative for disease-
associated pathologies, such as the case for pyridoxal-5¢-phos-
phate and pyrophosphate in hypophosphatasia, TGF in
geleophysic dysplasia or for FGF23 in hypophosphatemic
rickets. In particular, the latter example underscores the rele-
vance of identifying disease-associated biomarkers since
FGF23 is now considered to be one of the key regulators of
phosphate homeostasis in humans [118].
The use of Omics technologies and Systems analysis to
identify phenotype and/or genotype-specific disease profiles
promises to provide a plethora of novel putative biomarkers
that can be fully investigated through relevant cell and animal
models. Ultimately, personalized treatments and care strate-
gies will require relevant biomarkers to monitor efficacy of
treatment and disease progression. Therefore, novel
biomarkers are urgently required for detecting pre-clinical dis-
ease, to monitor disease progression and as a prerequisite for
clinical trials of new therapeutic targets. This lack of suitable
biomarkers is recognized as a major hindrance in translating
research into patient benefits.
11. European-wide networks generate critical
mass for diagnostic and research excellence:
the search for common therapeutic targets
In Europe, the skeletal genetics field has been fortunate over
the last 15 years to secure significant funding from the Euro-
pean Commission, via its various Framework Programs, to
establish three contiguous clinical and/or research networks
focused on rare skeletal diseases. The origin of these successful
large-scale collaborative projects lies with a Concerted Action
(1995 -- 2000), which provided the first opportunity for both
New therapeutic targets in rare genetic skeletal diseases
Expert Opinion on Orphan Drugs (2015) 3(10) 1147
D
ow
nl
oa
de
d 
by
 [N
ew
ca
stl
e U
niv
ers
ity
] a
t 0
7:3
1 1
6 O
cto
be
r 2
01
5 
clinical and research experts in GSDs to interact in a Pan-
European environment and this ultimately fostered important
collaborations and ground-breaking ideas that would lead to
future GSD networks.
The FP5-funded European Skeletal Dysplasia Network
(ESDN) for research and diagnosis (2002 -- 2006) was one
of the first networks of expertise in the field of rare diseases
to use information and communications technology tools
for the purposes of tele-expertise and medical diagnosis. Since
September 2003, ESDN has received over 2000 referrals
through an on-line Case Manager and 450 users have accessed
ESDN from 45 different countries worldwide. During this
initial funding period, research activities within ESDN devel-
oped several relevant mouse models of GSDs and identified
the first disease mechanisms, which would later be defined
as hallmark features of disease pathology and be tentatively
proposed as potential therapeutic targets.
EuroGrow (2007 -- 2010) was an FP6 project that focused
on the phenotyping of mouse models of a select group of
GSDs in order to develop and validate experimental
approaches for deep-phenotyping including omics-based anal-
ysis. This project successfully identified a range of common
disease mechanisms between phenotypically different GSDs
and laid the foundation for future large-scale projects.
The FP7-funded SYBIL project (Systems Biology for the
functional validation of genetic determinants of skeletal dis-
eases; http://www.sybil-fp7.eu) is a large-scale collaborative
project that aims to functionally validate genetic determinants
of common and rare skeletal diseases to gain a mechanistic
understanding of the disease processes and age-related changes
and to deliver new and validated therapeutic targets. The out-
comes of this project will include the generation and deep
phenotyping of a diverse range of cell and animal models of
GSDs that will generate new knowledge on disease mecha-
nisms. The major strength of this coordinated and multidisci-
plinary approach is the use of System Biology to underpin the
extensive ‘omics’-based analysis that will identify common
disease mechanisms and potential therapeutic targets in an
unbiased and iterative process.
Finally, National GSD networks such as the Skeletal Dys-
plasia Group (UK), SKELNET (Germany) and Skeldys.org
(Switzerland) have provided a combination of both formal
and informal discussion and diagnostic forums, whilst the
establishment within several EU countries of National
Centers of Excellence for specific GSDs has generated critical
mass for delivering clinical best practice and translational
research.
In summary, trans-European networks of clinical and
research excellence in GSDs have a proven track record in
delivering an efficient world class diagnostic service and
generating new knowledge on disease mechanisms that will
translate into novel therapeutic targets that might even be
shared amongst groups of different disease (i.e. Common
amongst the Rare). Moreover, interactions with patient self-
support groups, the International Rare Diseases Research
Consortium (IRDiRC) and the establishment of a European
Reference Network in the GSD domain will all help to
accelerate and deliver translational research through
broad international collaborations and the sharing of best
practice.
12. Clinical utility and patient expectations
The development of potential therapeutic targets to the point
at which clinical trials can be performed and pharmacological
agents ultimately brought to market is a notoriously challeng-
ing process with high attrition rates [119]. The low prevalence
of individual GSDs is a further challenge to the viable com-
mercial development of products in this area. In some cases,
it has been possible to apply drugs already used for the treat-
ment of related conditions to rare GSDs. For example, the use
of bisphosophonates in the treatment of adults and particu-
larly children with Osteogenesis Imperfecta (OI) has been
credited with reducing fracture frequency and improving
quality of life [120,121]; however, recent studies have called
this into question [122]. The example of the bisphosphonates
illustrates some of the challenges of demonstrating clinical
utility in the use of drugs in this group of diseases. This is
even more difficult in conditions where, unlike OI, the rela-
tively hard end points of fracture frequency and changes in
vertebral morphology are not applicable. It has been suggested
that changes in final adult height might be a relevant measure.
It is unlikely that changes of sufficient magnitude to truly alter
functional outcome will be achieved in many of the GSDs,
particularly when the condition is associated with very signif-
icant reductions not only in stature but also in reach. Alterna-
tive measures of improved symptom control, particularly
reduction in pain and neurological symptoms with improve-
ments in mobility, will need to be assessed. A particular chal-
lenge in this area will be the lack of availability of baseline data
from which assessments of change can be made, even for the
most common of the GSDs.
Recent discussions with support groups around the clinical
trials currently being carried out for the BioMarin product
BMN-111 have emphasized the importance of these issues.
Concerns have been expressed that undue focus on stature is
inappropriate in the context of the symptoms people with
ACH have on a daily basis, whilst a reduction of the neurolog-
ical impairment associated with neural axis compression
would be extremely welcome.
The rarity of the GSDs will pose significant challenges not
only to those developing therapeutic agents but also to
regulators and healthcare commissioners and providers. The
relatively small market available for drugs targeted at specific
molecular targets or even specific genetic pathways limits the
financial viability of such agents and is part of the wider
debate around the development of treatments for rare
diseases [123].
M. D. Briggs et al.
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13. Expert opinion
The extensive clinical variability and genetic heterogeneity of
GSDs, coupled with complex disease mechanisms, renders
this extensive group of rare diseases a bench to bedside chal-
lenge. Indeed, this large number of different and highly com-
plex phenotypes makes the identification, validation and
development of potential therapies almost impossible for any-
thing other than the most common GSDs. As an alternative
approach, we might consider identifying genotype- and/or
phenotype-independent ‘core disease mechanisms’ that are
shared amongst families of clinically unrelated GSDs. This
approach would allow the focusing of resources into several
areas of concerted investigation that have the potential to
identify and validate therapeutic targets with a broad applica-
tion to GSDs, inherited connective tissues as a whole and rare
genetic disease in general. Indeed, Ju¨rgen Spranger first sug-
gested the idea of ‘bone dysplasia families’ in 1985 [124] and
proposed that phenotypes with a similar clinical and
radiographic phenotype would likely have a similar disease
mechanism. Thirty years later, we can now expand upon
this pioneering concept and propose that common disease
mechanisms can also be shared amongst clinically different
phenotypes (‘common amongst the rare’).
In this context, ER stress has been associated with a diverse
range of genetic diseases and chronic conditions such as skel-
etal dysplasia (as discussed in this review), myopathy [125],
cerebro-vascular [42], kidney [126], ischaemia and cardiovascu-
lar diseases [127]. Moreover, ER stress is emerging as a very
attractive target that is being successfully exploited in a broad
range of diseases including neuropathy, juvenile-onset open-
angle glaucoma, obesity, diabetes, asthma and epidermolysis
bullosa, to name but a few. Historically many GSDs were
considered diseases of the ECM and proposed therapeutic
interventions involved the removal and/or correction of the
relevant mutated gene or abnormal gene product. This was
particularly the case with dominant-negative mutations in
the large structural proteins of the cartilage ECM such as
type II collagen [50]. However, emerging knowledge suggests
that the primary genetic defect may be less important than
the cells’ response to the expression of the mutant gene prod-
uct [107]. Moreover, the largely overlooked response of a cell
(i.e. chondrocyte) to the abnormal extracellular environment
is also important for disease progression as illustrated by
several GSDs discussed in this review.
It is important that ‘omics’-based approaches and technol-
ogies are systematically applied to the study of rare GSDs so
that definitive reference profiles and disease signatures are
generated for each phenotype. These can then be used in a
Systems Biology approach to identify both common and
dissimilar pathological signatures and disease mechanisms.
This approach is entirely dependent upon relevant in vitro
and in vivo models (and also novel ‘disease-mechanism
phenocopies’ [107]) for testing new diagnostic and prognostic
tools and for determining the molecular mechanisms that
underpin the pathophysiology so that effective therapeutic
treatments can be developed and validated. This approach
will eventually lead to personalized treatments and care strat-
egies centred on shared disease mechanisms with the use of
relevant biomarkers to monitor the efficacy of treatment and
disease progression.
It is vital that all relevant stakeholders are involved from the
outset in defining the appropriate outcomes of any potential
therapeutic regime. The perceptions of a successful therapy
can differ widely between the clinical academic community
and the relevant patient-support groups and it is vital that
there is engagement on all these issues.
In summary, the identification of causative genes and
mutations for GSDs over the last 20 years, coupled with the
generation and in-depth analysis of a plethora of relevant
cell and mouse models, has derived new knowledge on disease
mechanisms and suggested potential therapeutic targets. The
fast-evolving hypothesis that clinically disparate diseases can
share common disease mechanisms is a powerful concept
that will generate critical mass for the identification and
validation of novel therapeutic targets and biomarkers.
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